New scientific research on how the brain maintains stability amidst continuous environmental and physiological changes offers ...
Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for ...
Computer-assisted cognitive-behavior therapy (CCBT) and mobile mental health applications warrant continued development and ...
Researchers at Tel Aviv University have made a fundamental discovery: the NMDA receptor (NMDAR)—long studied primarily for ...
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...
The work by UB neuroscientists provides key insight into how the “lifesaving” medication offers almost instant relief of symptoms of major depression.
People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback